Introduction {#sec1}
============

Chronic kidney disease (CKD) is associated with increased levels of parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) and hypocalcemia, hyperphosphatemia, bone disease, vascular calcification, and cardiovascular morbidities collectively referred to as CKD-mineral and bone disorder [@bib1], [@bib2], [@bib3]. Recent reports suggested that increased levels of FGF-23 and decreased levels of soluble Klotho (s-Klotho) are common manifestations of CKD that develop earlier than increased levels of phosphate (Ps) or PTH [@bib4], [@bib5].

A transmembrane (TM) protein known as soluble α-Klotho (s-Klotho) is primarily produced in the kidney distal tubular cells [@bib6]. Soluble α-Klotho acts as a coreceptor for the bone-derived protein FGF-23 [@bib7], [@bib8]. Regulation of both renal handling of Ps and renal synthesis of calcitriol needs a cofunction of both FGF-23 and TM-Klotho [@bib9]. Soluble α-Klotho is the circulating protein resulting from the shedding of the extracellular domain of TM-Klotho operated by 2 metalloproteinases of the A disintegrin and metalloproteinase domain--containing protein (ADAM) family: ADAM10 and ADAM17 [@bib10]. In particular, s-Klotho inhibits the sodium-Ps cotransporter NaPi2a expression in the proximal tubules, thus generating a phosphaturic effect additive to and independent of FGF-23 [@bib11], [@bib12], [@bib13], and activates the ion channel TRPV5 in the distal tubules, thus increasing tubular reabsorption of calcium (Ca) [@bib14]. Therefore, α-Klotho, with its TM and soluble forms, is deeply involved with the physiological regulation of mineral metabolism [@bib15].

CKD is a common risk factor for cardiovascular diseases (CVD) such as coronary artery disease (CAD), cerebrovascular stroke, peripheral vascular disease, and heart failure [@bib16]. Although part of CVD burden in patients with CKD is related to traditional risk factors, CKD-associated disturbance in Ca--Ps homeostasis plays a crucial role as well [@bib2]. Recent studies showed that FGF-23 and its coreceptor s-Klotho have an important role in Ca--Ps homeostasis, and they could be the missing link in the detrimental relationship between CKD and CVD [@bib17].

Given the strong cardioprotective effects of Klotho demonstrated in preclinical studies, the present study aimed to assess the association between s-Klotho and carotid intima--media thickness (CIMT) and left ventricular (LV) dysfunction in patients with end-stage renal disease (ESRD) on regular hemodialysis (HD). It was hypothesized that low levels of s-Klotho are associated with a larger burden of CVD in these patients.

Methods {#sec2}
=======

Study population {#sec2.1}
----------------

This is a cross-sectional study conducted on 88 patients with ESRD on regular HD of at least 6-month duration. All patients have been attending the nephrology dialysis unit in the Theodor Bilharz Research Institute, Giza, Egypt. All patients received 3 sessions of HD/wk, each of 4-hour duration using a polysulfone dialyzer (Fresenius, St. Wendel, Germany) with surface area of 1.4--1.6. Patients with advanced congestive heart failure \[defined clinically by elevated jugular venous pressure, ascites, peripheral edema, and shortness of breath at rest and LV ejection fraction (LVEF) of \<30% in echocardiography requiring hospital-based support, a heart transplant, or palliative care according to guidelines of the American College of Cardiology/American Heart Association\] [@bib18], sepsis, or malignancy were excluded from the study. Informed written consent was obtained from all participants. The study protocol was approved by the institute ethics committee, and the study was performed in accordance with the Declaration of Helsinki.

The studied patients were divided according to the median s-Klotho level (cut point, 476 pg/mL) into 2 groups: patients with low s-Klotho \<476 pg/mL (Group I, *n* = 44) and patients with high s-Klotho \>476 pg/mL (Group II, *n* = 44).

A control group consisting of 28 normal individuals was used to give our reference values for s-Klotho, FGF-23, CIMT, and echocardiographic findings. There were 17 men and 11 women with a mean age of 53.3 ± 16.2 years, with normal renal function and no evidence of acute or chronic underlying disease.

Each patient underwent a thorough history and clinical examination. Demographic characteristics and coexisting conditions such as atherosclerotic CAD diagnosed by electrocardiography and coronary angiography within 3 months of enrollment in the study were collected.

Fasting blood samples were collected from the patients before the HD session, immediately centrifuged, aliquoted in vials, and stored at --60°C until the time of analysis. Thawing the test samples was carried out at a low temperature by mixing them completely before measurement. Routine examinations included complete blood analysis, kidney function tests (serum urea, creatinine, sodium and potassium, and uric acid), random blood sugar, serum electrolytes, lipid profile, and serum albumin. Serum levels of Ca, Ps, PTH, and C-reactive protein were measured.

Serum levels of s-Klotho and FGF-23 measurement {#sec2.2}
-----------------------------------------------

The serum levels of s-Klotho were measured using an Enzyme linked immunosorbent assay (ELISA) system (Immuno-Biological Laboratories, Gunma, Japan) [@bib19], and this assay detects circulating s-Klotho using 2 monoclonal antibodies that specifically recognize the extracellular domain of Klotho, with a lower limit of detection of 6.15  pg/mL and the intra-assay and interassay coefficients of variation of \<10%. The serum levels of FGF-23 were measured using a commercial sandwich ELISA kit (Kainos Laboratories, Inc., Tokyo, Japan) [@bib20] that uses a 2-site ELISA for the full-length molecule. Two specific murine monoclonal antibodies recognize the biologically active FGF-23, with a lower limit of detection of 3  pg/mL and interassay and intra-assay coefficients of variation of \<5%.

Residual renal function estimation {#sec2.3}
----------------------------------

Residual renal function (RRF) was estimated by calculating glomerular filtration rate expressed in mL/min/1.73 m^2^. Glomerular filtration rate was estimated as the mean of urea and creatinine clearance using 24-hour urine collections and the mean of the post- and pre-HD plasma urea and creatinine. RRF was considered zero in patients with a urinary output \<100 mL/24 h [@bib21]. Kt/V was used to assess dialysis adequacy [@bib22].

Echocardiography {#sec2.4}
----------------

After the HD session, each patient underwent echocardiography to determine LV mass (LVM), LVM index (LVMI), and LVEF. For determination of LVM, the Devereux formula was used [@bib23]. LVM (g): 1.04 \[(LVID + PWT + IVST)^3^ -- LVID^3^\] -- 14, where LVID indicates LV internal dimension, PWT indicates posterior wall thickness, and IVST indicates interventricular septal thickness. LVM was divided by body surface area to measure LVMI. According to the current guidelines, LV dysfunction was defined as an LVEF  \< 45%.

Measurement of CIMT {#sec2.5}
-------------------

After the HD session, each patient underwent ultrasonography of the carotid arteries using a high-resolution real-time scanner with a 7.5-MHz transducer [@bib24]. The examination was done with the patient in the supine position, and the common carotid artery and carotid bifurcation were scanned on both sides. The carotid artery was scanned in the longitudinal and transverse directions. The site of the most advanced atherosclerotic lesion that showed the greatest distance between the lumen--intima interface and the media--adventitia interface was the maximum intima--media thickness (IMT) value. When plaque was detected on ultrasonography, it was observed as localized thickening rather than a circumferential change in the vessel wall. The greatest thickness of the intima--media complex (including plaque) was used for the maximum IMT value. We identified patients having atherosclerosis based on atheromatous plaques of focal increases in IMT ≥ 1.1 mm in accordance with a prior study that showed the normal limit of IMT to be ≤1.0 mm [@bib25].

Statistical analysis {#sec2.6}
--------------------

Data are presented as means ± standard deviations or number (%). The 2-tailed Student\'s *t* test was used to compare the mean values of 2 groups (GraphPad Quick calc; Graphpad Software Inc., San Diego, CA, USA). Categorical data were compared using the chi-square test. The Spearman rank correlation test was used to analyze the correlations between s-Klotho levels and markers of mineral metabolism. Multivariate regression analysis (using MedCalc software; MedCalc software bvba, Acacialaan, Ostend, Belgium) was used to analyze the association between s-Klotho and markers of CVD, with a linear regression analysis model with unstandardized betas and a 95% confidence interval (CI) for CIMT, LVM, LVMI, and LVEF and a logistic regression analysis model was used for CAD. The linear regression analysis model was also used to determine the association between FGF-23 and CIMT, LVM, LVMI, and LVEF and the logistic regression analysis model was used for CAD. Statistical analyses of data were performed using SPSS for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA). A *P* value\< 0.05 was considered to be significant, and *P* \< 0.01 was considered to be highly significant.

Results {#sec3}
=======

Demographic characteristics of HD patients and controls included in this study are shown in [Table 1](#tbl1){ref-type="table"}, where the mean age of studied patients was 58.6 ± 19.3 years. Fifty-one (58.0%) patients were men and 37 (42.1%) were women. The most common causes of ESRD were diabetes mellitus, hypertension, and glomerulonephritis ([Table 1](#tbl1){ref-type="table"}).

Mean value of s-Klotho was significantly low in HD patients compared to the control group (477.9 ± 76.2 vs. 863.7 ± 261.8, *P* = 0.001), and mean value of FGF-23 was significantly high in HD patients compared to the control group (60.5 ± 17.6 vs. 35.8 ± 13.9, *P* = 0.001; [Table 2](#tbl2){ref-type="table"}).

Patients with a low s-Klotho (\<476 pg/mL) were older (63.2 ± 9.4 vs. 53.8 ± 16.2, *P* = 0.001) and had high FGF-23, PTH, Ps, and C-reactive protein and low Ca and RRF ([Table 2](#tbl2){ref-type="table"}) compared to Group II. There were no significant differences in the mean values of serum creatinine, lipid profile, hemoglobin, serum glucose, serum albumin, serum uric acid, and Kt/V between the 2 groups ([Table 2](#tbl2){ref-type="table"}).

s-Klotho and markers of mineral metabolism {#sec3.1}
------------------------------------------

The mean values of serum levels of PTH, FGF-23, and Ps were significantly high in patients of Group I compared to patients of Group II, whereas the mean value of serum levels of Ca was significantly low in Group I compared to Group II ([Table 2](#tbl2){ref-type="table"}).

Using the Spearman rank correlation test, we found that there was significant negative correlation between s-Klotho and FGF-23 (*r* = --0.717, *P* = 0.001, 95% CI for *r* = --0.806 to --0.598; [Fig. 1](#fig1){ref-type="fig"}), PTH (*r* = --0.484, *P* = 0.001, 95% CI for *r* = --0.630 to --0.306; [Fig. 2](#fig2){ref-type="fig"}), and Ps (*r* = --0.548, *P* = 0.001, 95% CI --0.680 to --0.383; [Fig. 3](#fig3){ref-type="fig"}), whereas there was significant positive correlation between s-Klotho and Ca (*r* = 0.294, *P* = 0.005, 95% CI 0.0903--0.474; [Fig. 4](#fig4){ref-type="fig"}).

s-Klotho and markers of CVD {#sec3.2}
---------------------------

The mean values of CIMT, LVM, LVMI, and LVEF were high in patients of Group I compared to patients of Group II. The prevalence of CAD was higher among patients with low s-Klotho \[36 (81.1%) vs. 22 (50.0%), *P* = 0.004; [Table 3](#tbl3){ref-type="table"}\].

Using the Spearman rank correlation test, we found that there was significant positive correlation between s-Klotho and LVEF (*r* = 0.392, 95% CI 0.199--0.556, *P* = 0.001; [Fig. 5](#fig5){ref-type="fig"}).

[Table 4](#tbl4){ref-type="table"} shows the results of the multivariate regression analysis of s-Klotho with CIMT, LVM, LVMI, LVEF, and CAD as different markers for CVD. After adjustments for age, gender, mean blood pressure, and duration of HD, s-Klotho showed significant association with CIMT, LVEF, and CAD, but not with LVM and LVMI.

FGF-23 and markers of mineral metabolism {#sec3.3}
----------------------------------------

Using the Spearman rank correlation test, we found that there was positive correlation between FGF-23 and Ps (*r* = 0.497, *P* = 0.001, 95% CI 0.321--0.640) and PTH (*r* = 0.405, *P* = 0.001, 95% CI 0.214--0.567), whereas there was negative correlation between FGF-23 and Ca (*r* = --0.237, *P* = 0.026, 95% CI --0.426 to --0.029).

FGF-23 and CVD markers {#sec3.4}
----------------------

[Table 4](#tbl4){ref-type="table"} shows the results of multivariate regression models of FGF-23, total cholesterol, triglycerides, and blood glucose with CIMT, LVM, LVMI, LVEF, and CAD as different markers for CVD. After adjustments for age, gender, mean blood pressure, and duration of HD, FGF-23, total cholesterol, triglycerides, and blood glucose were not independently associated with CIMT, LVM, LVMI, LVEF, and CAD.

Discussion {#sec4}
==========

In the present study, we measured the s-Klotho levels and determined the association between s-Klotho levels and markers of mineral metabolism (FGF-23, PTH, Ca, and Ps) and CVD (CIMT, CAD, LVM, LVMI, and LVEF) in patients with ESRD on regular HD. Our study showed that there was significant negative correlation between s-Klotho levels and serum levels of FGF-23, PTH, and Ps and positive correlation between s-Klotho and serum levels of Ca. In addition, the present study showed that lower levels of s-Klotho are significantly associated with signs of CVD such as increased CIMT, more CAD, and LV dysfunction.

Our study showed that serum levels of s-Klotho were significantly decreased in patients with ESRD on regular HD compared to the control group, as previously reported in CKD patients [@bib26] and patients on HD [@bib27], [@bib28], [@bib29]. It has been reported that s-Klotho levels are severely reduced in patients with CKD compared to control subjects [@bib30]. However, it appears that s-Klotho levels are not completely depleted, even in patients with ESRD on HD [@bib27], [@bib28], [@bib29]. This finding suggests that in humans, a basal level of s-Klotho may be produced from other organs than the kidneys, such as the brain and parathyroid glands, as previously reported in mice [@bib15], [@bib31], [@bib32]. Recent studies revealed that s-Klotho has been decreased in the early stage of CKD, even before rising of Ps or PTH and emerged as a powerful player in Ca--Ps homeostasis that is thought to contribute to the high burden of CVD in CKD patients [@bib5], [@bib17]. This study showed that patients with a low s-Klotho (\<476 pg/mL) had a high age and low RRF compared to Group II, and there was no significant differences in the mean values of Kt/V between the 2 groups. Our results are in agreement with the results of Lindberg et al [@bib28], who reported that patients with high s-Klotho were more with good RRF, and Sawires et al [@bib29], who reported that there was no significant correlation between s-Klotho and Kt/V and there was significant negative correlation between s-Klotho and age.

The present study showed that patients with a low s-Klotho were more often associated with CIMT, LV dysfunction, and CAD, and it seems that there was independent association between s-Klotho and CIMT, LVEF, and CAD using multivariate regression analysis. Our results are in agreement with results of Kitagawa et al [@bib33] who reported that the serum Klotho level was found to significantly correlate with markers of CKD-mineral and bone disorder and is an independent biomarker of arterial stiffness in patients with CKD. In contrary to our results, Buiten et al [@bib34] reported that s-Klotho was not independently associated with CVD in dialysis patients and did not support a direct cardioprotective effect of s-Klotho.

Many clinical studies have suggested that s-Klotho exerts strong cardioprotective effects. For instance, s-Klotho has been shown to protect against vascular calcifications in rodent models of CKD, whereas in humans without CKD, higher s-Klotho levels have been related to a lower incidence of mortality and CVD [@bib28], [@bib35], [@bib36], [@bib37]. Moreover, low s-Klotho levels have been associated with increased arterial stiffness in CKD patients [@bib33]. Further support for a direct role of Klotho in vascular homeostasis comes from *in vitro* studies showing endogenous expression of s-Klotho in human vascular smooth muscle cells [@bib38]. Interestingly, inhibition of s-Klotho expression in aortic vascular smooth muscle cells resulted in accelerated calcification of these cells [@bib38]. However, the exact role of s-Klotho in the progression of CVD in dialysis patients remains to be elucidated.

There many reports that CVD starts to develop in early stages of CKD and that s-Klotho starts to decrease also in early stages of CKD. Therefore, patients with ESRD on regular HD have been exposed to low s-Klotho levels for a prolonged period, predisposing them to vascular calcifications and atherosclerosis.

The role of s-Klotho in the development of atherosclerotic disease in dialysis patients might be overshadowed by the large amount of other pathophysiological stimuli for CVD prevalent in these patients, such as obesity, diabetes, dyslipidemia, and hypertension. This might explain the disparity between data found in rodents with only Klotho deficiency and patients suffering from a wide variety of comorbidities. However, our study showed that there were no significant differences in the mean values of lipid profile, blood glucose, mean blood pressure, body mass index, and duration of dialysis between the 2 groups. Using multivariate regression analysis, we found that there was no independent association between FGF-23, blood glucose, total cholesterol, and triglycerides and CVD markers. These findings may explain that s-Klotho seems to be independently associated with CIMT, LVEF, and CAD as markers of CVD.

In our study, s-Klotho is significantly correlated with markers of mineral metabolism, which is consistent with many studies in CKD patients [@bib5], [@bib33] that reported that s-Klotho correlated negatively with PTH and Ps and positively with Ca, whereas no correlation was found between s-Klotho and 1,25 dihydroxycholecalciferol and fractional excretion of Ca. Also our study is consistent with studies in HD patients [@bib34] that reported that the serum s-Klotho level was significantly associated with a lower plasma 25 hydroxy vitamin D \[25(OH)D\] and lower PTH [@bib29].

In addition, in our study, FGF-23 was significantly associated with markers of mineral metabolism, and FGF-23 was not independently associated with markers of CVD. Our results are consistent with studies in HD patients [@bib34] that reported that FGF-23 showed a strong positive association with Ps and PTH and FGF-23 was not independently associated with CVD. In addition, our results are comparable with the results from studies in CKD patients, where FGF-23 levels correlated positively with PTH and Ps and negatively with 1,25 dihydroxycholecalciferol and no correlation existed with Ca and fractional excretion of Ca [@bib5].

This study has some limitations. We studied only a small sample of patients. Data on dietary Ca, Ps, and medication intake, which may affect the levels of serum Ps, Ca, s-Klotho, and FGF-23 were not collected. Ps and PTH were not statistically analyzed as risk factors for CVD.

In conclusion, the present study showed that patients with a low s-Klotho were more often associated with increased CIMT, LV dysfunction, and CAD, and it seems that there was an independent association between s-Klotho and CIMT, LVEF, and CAD.
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![**Correlation coefficient between the serum level of s-Klotho and FGF-23.***r* = --0.717, 95% confidence interval, --0.806 to --0.598, *P* = 0.001.\
FGF-23, fibroblast growth factor-23; s-Klotho, soluble Klotho.](gr1){#fig1}

![**Correlation coefficient between the serum level of s-Klotho and PTH.***r* = --0.484, 95% confidence interval --0.630 to --0.306, *P* = 0.001.\
PTH, parathyroid hormone; s-Klotho, soluble Klotho.](gr2){#fig2}

![**Correlation coefficient between the serum levels of s-Klotho and Ca.***r* = 0.294, 95% confidence interval 0.0903--0.474, *P* = 0.005.\
Ca, calcium; s-Klotho, soluble Klotho.](gr3){#fig3}

![**Correlation coefficient between the serum levels of s-Klotho and Ps.***r* = --0.548, 95% confidence interval --0.680 to --0.383, *P* = 0.001.\
Ps, phosphate; s-Klotho, soluble Klotho.](gr4){#fig4}

![**Correlation coefficient between s-Klotho and LVEF.***r* = 0.392, 95% confidence interval 0.199--0.556, *P* = 0.001.\
LVEF, left ventricular ejection fraction; s-Klotho, soluble Klotho.](gr5){#fig5}

###### 

Demographic characteristics of the studied patients and control group

  Variable                    Studied patients (*n* = 88)   Control group(*n* = 28)   *P*
  --------------------------- ----------------------------- ------------------------- -------
  Age (y)                     58.6 ± 19.3                   53.3 ± 16.2               0.192
  Gender (M/F)                51/37 (58.0/42.1)             17/11 (60.7/39.3)         1.000
  BMI (g/m^2^)                24.6 ± 5.2                    26.2 ± 5.6                0.167
  SBP (mmHg)                  124.6 ± 15.5                  119.2 ± 11.3              0.091
  DBP (mmHg)                  85.7 ± 25.4                   80.4 ± 19.1               0.312
  Mean BP (mmHg)              98.7 ± 28.8                   93.4 ± 22.6               0.376
  Duration of dialysis (mo)   59.5 ± 35.4                   --                        --
  Anuria                      30 (34.1)                     --                        --
  Etiology of ESRD                                                                    
   DM                         33 (37.5)                                               
   HTN                        27 (30.7)                                               
   GN                         15 (17.0)                                               
   CIN                        5 (5.7)                                                 
   SLE                        3 (3.4)                                                 
   APKD                       2 (2.3)                                                 
   Unknown                    3 (3.4)                                                 

Data are presented as means ± SD or number (%).

APKD, adult polycystic kidney disease; BMI, body mass index; BP, blood pressure; CIN, chronic interstitial nephritis; DBP, diastolic blood pressure; DM, diabetes mellitus; ESRD, end-stage renal disease; GN, glomerulonephritis; HTN, hypertension; SBP, systolic blood pressure; SLE, systemic lupus erythematosus.

###### 

Laboratory parameters of the studied patients and control group

  Variables                All patients (*n* = 88)   Control group (*n* = 28)   *P*     Group I (s-Klotho \< 476 pg/mL, *n* = 44)   Group II (s-Klotho \> 476 pg/mL, *n* = 44)   *P*
  ------------------------ ------------------------- -------------------------- ------- ------------------------------------------- -------------------------------------------- -------
  sCr (mg/dL)              7.9 ± 1.8                 0.8 ± 0.3                  0.001   7.5 ± 1.2                                   8.3 ± 3.1                                    0.114
  S. Ca (mg/dL)            8.4 ± 1.0                 8.5 ± 0.6                  0.618   8.1 ± 0.8                                   8.7 ± 1.3                                    0.014
  S. Ps (mg/dL)            1.9 ± 1.1                 0.9 ± 0.2                  0.001   2.1 ± 0.5                                   1.8 ± 0.6                                    0.013
  S. PTH (pg/mL)           71.7 ± 25.1               31.2 ± 23.4                0.001   76.9 ± 21.3                                 67.1 ± 24.5                                  0.048
  RRF (mL/min/1.73 m^2^)   2.1 ± 1.5                                                    2.4 ± 1.8                                   3.1 ± 1.3                                    0.040
  Kt/V                     1.6 ± 0.6                                                    1.5 ± 0.4                                   1.6 ± 0.5                                    0.101
  T. cholesterol (mg/dL)   154.4 ± 16.4              122.3 ± 14.6               0.001   151.4 ± 17.4                                148.3 ± 17.3                                 0.404
  LDL-C (mg/dL)            123.3 ± 37.3              101.5 ± 27.8               0.005   124.4 ± 36.8                                122.2 ± 36.6                                 0.779
  TGs (mg/dL)              116.5 ± 20.5              91.7 ± 16.3                0.001   117.7 ± 22.3                                115.3 ± 19.2                                 0.590
  Hb (g/dL)                11.2 ± 1.5                13.8 ± 1.2                 0.001   10.8 ± 1.5                                  11.2 ± 1.4                                   0.199
  Bl. glucose (mg/dL)      136.7 ± 26.4              118.6 ± 21.3               0.001   132.1 ± 27.3                                141.4 ± 25.8                                 0.102
  C-RP (mg/L)              16.1 ± 4.2                0.71 ± 0.4                 0.001   20.9 ± 5.1                                  17.3 ± 6.2                                   0.004
  S. albumin (g/dL)        3.8 ± 0.7                 4.2 ± 0.6                  0.008   3.7 ± 0.4                                   3.9 ± 0.9                                    0.182
  S. uric acid (mg/dL)     6.8 ± 1.0                 5.7 ± 1.2                  0.001   6.7 ± 0.7                                   7.1 ± 1.4                                    0.094
  S-Klotho (pg/mL)         477.9 ± 76.2              863.7 ± 261.8              0.001   427.8 ± 46.2                                535.4 ± 61.4                                 0.001
  S. FGF-23 (pg/mL)        60.5 ± 17.6               35.8 ± 13.9                0.001   67.8 ± 24.2                                 50.3 ± 11.2                                  0.001

Data are presented as mean ± SD. Bl., blood; Ca, calcium; C-RP, C-reactive protein; FGF-23, fibroblast growth factor-23; Hb, hemoglobin; LDL-C, low-density lipoprotein cholesterol; Ps, phosphorus; PTH, parathyroid hormone; RRF, residual renal function; S., serum; sCr, serum creatinine; s-Klotho, soluble Klotho; T., total; TG, triglyceride.

###### 

Echocardiographic findings, CIMT, and CAD of the studied patients and control group

  Variable        All patients (*n* = 88)   Control group (*n* = 28)   *P*     Group I (s-Klotho \< 474, *n* = 44)   Group II (s-Klotho \> 474, *n* = 44)   *P*
  --------------- ------------------------- -------------------------- ------- ------------------------------------- -------------------------------------- -------
  LVM (g)         193.4 ± 22.3              112.7 ± 23.6               0.001   198.6 ± 26.3                          188.2 ± 18.3                           0.034
  LVMI (g/m^2^)   110.4 ± 21.5              66.4 ± 21.3                0.001   120.7 ± 23.2                          110.2 ± 18.6                           0.022
  LVEF (%)        49.6 ± 10.2               58.6 ± 6.3                 0.001   45.9 ± 10.3                           55.2 ± 9.3                             0.001
  CIMT (mm)       1.0 ± 0.2                 0.8 ± 0.2                  0.001   1.2 ± 0.2                             0.9 ± 0.1                              0.001
  CAD             58 (65.9)                 --                                 36 (81.1)                             22 (50.0)                              0.004

Data are presented as means ± SD or number (%).

CAD, coronary artery disease; CIMT, carotid intima--media thickness; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMI, left ventricular mass index; s-Klotho, soluble Klotho.

###### 

Multivariate linear regression analysis of the predictive factors for CIMT, LVM, LVMI, LVEF, and CAD

  Variables        CIMT      LVM     LVMI      LVEF    CAD                                         
  ---------------- --------- ------- --------- ------- --------- ------- --------- ------- ------- -------
  s-Klotho         --0.213   0.040   --0.184   0.070   --0.123   0.080   0.251     0.040   0.342   0.050
  FGF-23           0.132     0.060   0.114     0.070   0.134     0.070   --0.162   0.060   0.451   0.060
  T. cholesterol   0.075     0.130   0.033     0.160   0.124     0.080   0.004     0.310   0.312   0.090
  Triglycerides    0.046     0.150   0.113     0.090   0.031     0.210   0.006     0.110   0.123   0.110
  Bl. glucose      0.012     0.230   0.026     0.140   0.017     0.260   0.015     0.090   0.412   0.060

Adjusted for age, gender, mean blood pressure, and duration of dialysis.

Bl., blood; CAD, coronary artery disease; CIMT, carotid intima--media thickness; FGF-23, fibroblast growth factor-23; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMI, left ventricular mass index; OR, odds ratio; s-Klotho, soluble Klotho; T., total.
